Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10382 versus investigator-selected TKIs in newly diagnosed Philadelphia chromosome-positive chronic-phase CML
CTR20263872Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of TERN-701 in chronic myelogenous leukemia (CML) (2 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Major molecular response rate at Week 48. Started Oct 2026; status: active.
02
Drugs
TERN-701
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on CTR20263872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263872.